Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy

On March 18, Medicilon Inc. (Medicilon) and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.

Two-way development, move forward together
Improve the efficiency of RNA, cell and genetic drug research and development

In the exploration of the field of biopharmaceutical, RNA, cell and gene therapy are gradually becoming emerging forces leading the development of the industry with their unique advantages and potential.  These cutting-edge therapies not only open up new path for disease treatment, but also provide new opportunities for biopharmaceutical companies.

As a CRO deeply involved in the field of biopharmaceutical preclinical R&D, Medicilon keeps up with the trends and involved in cutting-edge fields such as bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT.  Medicilon has helped 421 INDs pass the approval of China's NMPA, the US FDA, the EU's EMA and the Australian TGA to enter clinical trials.

Innoforce is a global biopharmaceutical contract development and manufacturing organizations (CDMO) serving domestic and foreign clients.  Focusing on areas such as RNA and cell therapy products, Innoforce is committed to providing one-stop CDMO solutions including plasmids, viral vectors, cell therapy products, RNA and LNP to advanced therapy drug partners.

Dedicated to empowering the cutting-edge areas of drug research and development, Medicilon and Innoforce have reached a strategic collaboration based on the same vision and complementary technical advantages.  According to the strategic collaboration agreement, the two parties will conduct all-round strategic collaboration in business collaboration, resource sharing, global promotion, joint development and commercial licensing.  This collaboration not only achieves the complementary advantages and efficient integration of the resources of both parties, but also demonstrates profound insights and firm confidence in the fields of advanced therapies such as RNA, cell and gene therapy, and will also lead the entire biopharmaceutical industry towards higher and further goals.